ArticleFrontiers in pharmacology2025
Scorpion-Centipede extracts mitigate ovariectomy-induced osteoporosis in mice through facilitating Cx3cr1 expression.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Scorpion and Centipede (SC) is an ancient formula of traditional Chinese medicine that is commonly utilized in a range of disorders, and it has been shown to have pharmacological effects on postmenopausal osteoporosis (PMOP). However, the specific mechanism of SC for the treatment of PMOP remains to be further investigated. This study aimed to investigate the therapeutic potential of a traditional Chinese medicine formula consisting of SC in regulating the osteogenic and adipogenic differentiation of bone marrow mesenchymal stem cells (BMMSCs) to treat PMOP. Methods: The ovariectomy-induced mice (OVX) were established and divided into a sham surgery group, OVX, OVX with alendronate sodium, and OVX with SC, and kept for 10 weeks. Results: The results showed that SC treatment significantly improved bone mineral density (BMD), trabecular separation (Tb.Sp), trabecular thickness (Tb.Th), trabecular number (Tb.N), bone volume fraction (BV/TV), and trabecular pattern factor (Tb.Pf) in OVX mice. In addition, SC treatment markedly increased Runx2, Osx, Alp, and Cx3cr1 while decreasing adipogenic genes like PPARγ and C/EBPα in the bone tissue of OVX mice and BMMSCs. Notably, the effects of SC on osteogenic and adipogenic genes were blocked in Cx3cr1 knockdown MC3T3-E1 and 3T3-L1 cells. Conclusion: This study demonstrates that the SC effectively increases bone mass and osteogenesis by promoting Cx3cr1, thereby increasing osteogenic differentiation and inhibiting adipogenic differentiation. These findings amplified the mechanisms of SC and its potential to treat PMOP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.